Dojolvi FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved June 30, 2020)
Brand name: Dojolvi
Generic name: triheptanoin
Dosage form: Oral Liquid
Company: Ultragenyx Pharmaceutical Inc.
Treatment for: Long-Chain Fatty Acid Oxidation Disorders
Dojolvi (triheptanoin) is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Development Timeline for Dojolvi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.